DSM-Firmenich
Company
DSM-Firmenich develops 3 assets, the furthest approved (riboflavin). Mostly supplement.
- 3
- Assets
- Furthest stage
- Approved
- 6
- Trials
- 18
- Signals
Pipeline
3Precursor of flavin cofactors FMN and FAD required for cellular oxidation-reduction reactions.
Approved, Supplement, keratoconus (Phase 3), gut microbiota (Phase 2)
Carotenoid supplementation supports antioxidant activity in retinal and neural tissues.
Phase 2, Supplement, mild cognitive impairment (Clinical, no phase)
Acts as an NAD+ precursor, supporting cellular NAD+ levels and mitochondrial function.
Phase 1, Supplement, nad+ metabolism, pharmacokinetic
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
13 assets, 6 trials
In the full profile
- Evidence behind the mechanisms3
- Trials22
- Signals20
- Similar companies6